A material transfer agreement is the legal contract that must be signed before tangible research materials — cell lines, reagents, biological samples, software, or datasets — move between two organisations. It fixes who owns the material and any derivatives, sets what the recipient may do with it, and allocates liability. A material transfer agreement (MTA) is required whenever proprietary or regulated research material crosses an institutional boundary, whether between two universities, from academia to industry, or the reverse.
Definition: a material transfer agreement is a contract that governs the transfer of tangible research materials between two organisations when the recipient intends to use the material for their own research purposes.
Jump to:
- What is a material transfer agreement?
- When is a material transfer agreement required?
- What clauses does a standard MTA contain?
- How does UK practice differ from US practice?
- Material transfer agreement FAQs
What is a material transfer agreement?
A material transfer agreement sits between two parties: a provider, who supplies the material, and a recipient, who receives it for research, testing, or evaluation. Almost no research organisation will release physical material — a plasmid, an antibody, a chemical compound, a mouse line, patient-derived tissue, or bundled software and data — without one in place.
Three types of MTA are most common at academic institutions: transfers between academic or research institutions, transfers from academia to industry, and transfers from industry to academia. Each carries different negotiating priorities, since a commercial provider will typically restrict use and reserve rights over derivatives more tightly than a non-profit research institute would.
When is a material transfer agreement required?
An MTA is required whenever material is not already covered by a broader collaboration agreement, consortium agreement, or funding contract that addresses ownership and use of transferred materials. It becomes mandatory, rather than merely advisable, in three recurring situations.
- Human tissue transfers: in the UK, transfer of human tissue or cells for research is governed by the Human Tissue Act 2006, and an MTA (or equivalent material transfer form) is needed to evidence lawful, consented use and to satisfy Human Tissue Authority licensing conditions.
- Materials with commercial or patent potential: where the material, or a discovery derived from it, could be patented, an MTA is used to fix inventorship, licensing, and revenue-sharing terms before any transfer takes place.
- Cross-institutional research collaborations: whenever a researcher sends or receives compounds, cell lines, reagents, or proprietary datasets from an external organisation without an overarching agreement already in force.
Institutional practice is consistent on one point: individual principal investigators cannot sign MTAs on behalf of their university. UK universities route requests through a research contracts or Research and Innovation Services (RIS) office; US institutions route them through a Technology Transfer Office (TTO). This centralisation protects the institution’s intellectual property position and ensures the agreement is enforceable.
What clauses does a standard MTA contain?
Most MTAs, regardless of jurisdiction, follow a recognisable clause structure. Understanding this structure is the fastest way for a research administrator to review a third-party MTA against institutional norms rather than starting from a blank page.
- Permitted use: restricts the material to a defined research purpose, typically excluding commercial use, further distribution, or use in human subjects without separate approval.
- Ownership and derivatives: confirms the provider retains ownership of the original material, and defines who owns modifications, progeny, and unmodified derivatives.
- Intellectual property and inventions: allocates rights over any patentable invention arising from use of the material, often with a first option to license back to the provider.
- Publication rights: preserves the recipient’s right to publish results, sometimes subject to a short pre-publication review period for the provider to flag confidential information.
- Confidentiality: protects any proprietary information disclosed alongside the material.
- Warranties, indemnities and liability: the provider typically disclaims warranties on the material’s fitness for purpose and safety, while the recipient indemnifies the provider against misuse.
- Term, termination and disposition: specifies how long the agreement runs, and whether unused material must be returned or destroyed at the end of the project.
These clauses collectively protect the parties’ research and commercial interests in the material while ensuring compliance with applicable regulatory requirements, from data protection through to biosafety.
How does UK practice differ from US practice?
The underlying clause structure is similar on both sides of the Atlantic, but the institutional machinery around MTAs differs in three practical respects: which model agreement negotiators start from, which office holds signing authority, and which professional body supports that office.
| Aspect | UK practice | US practice |
|---|---|---|
| Model agreement | Lambert Toolkit model materials transfer agreements, published by the UK Intellectual Property Office | Uniform Biological Material Transfer Agreement (UBMTA), developed by the National Institutes of Health (NIH) |
| Signing authority | University Research and Innovation Services / research contracts team | Institutional Technology Transfer Office (TTO) |
| Human tissue regulation | Human Tissue Act 2006, overseen by the Human Tissue Authority | Institutional Review Board (IRB) oversight under the federal Common Rule |
| Professional body | ARMA (Association of Research Managers and Administrators) | NCURA (National Council of University Research Administrators) and AUTM |
| Template repository | ARMA’s published MTA templates, including a non-human tissue MTA | AUTM’s MTA toolkit and public list of UBMTA signatory institutions |
The UBMTA is a master agreement: once a US institution signs it, subsequent transfers between fellow signatories only require a short implementing letter rather than a fresh negotiation, which is why AUTM’s signatory list matters operationally. The UK has no single equivalent master agreement; Lambert Toolkit models function as drafting templates rather than a pre-signed master framework, so each UK MTA is typically negotiated afresh, even between repeat institutional partners. ARMA, NCURA, and their European counterpart EARMA are all national associations affiliated to INORMS, the International Network of Research Management Societies, reflecting how widely MTA negotiation sits within the research administration profession globally.
Material transfer agreement FAQs
What is a material transfer agreement?
A material transfer agreement is a contract that governs the transfer of tangible research materials — such as reagents, cell lines, plasmids, vectors, chemical compounds, or software — between two organisations when the recipient intends to use the material for its own research purposes.
What is the difference between MTA and NDA?
An MTA governs the physical transfer of tangible material and covers ownership, permitted use, and derivatives, while a non-disclosure agreement (NDA) governs only the confidentiality of shared information. Many MTAs incorporate confidentiality terms directly, making a separate NDA unnecessary for that transfer.
What is the standard material transfer agreement?
There is no single global standard MTA. The closest equivalent is the US Uniform Biological Material Transfer Agreement (UBMTA), a pre-agreed master framework maintained by AUTM. UK institutions instead draft from Lambert Toolkit model clauses or their own institutional precedent, negotiating each transfer individually.
What is the purpose of an MTA?
An MTA’s purpose is to regulate the use and distribution of transferred material, define legal provisions such as warranties, indemnities and risk allocation, specify each party’s access to results, and settle ownership of any resulting intellectual property and publication rights.
What this means for research offices
Material transfer volumes are rising as biological data-sharing mandates and open-research policies push more labs to exchange materials alongside associated datasets. As funders increasingly expect materials and data underlying published results to be shareable, research offices should expect MTA review queues — and negotiation over restrictive provider terms — to keep growing rather than shrink. Building clause-level familiarity now, rather than treating every incoming MTA as a bespoke legal puzzle, is the most efficient way for a research administration office to keep transfers moving without exposing the institution to unmanaged IP or liability risk.
